Postnatal steroid treatment in preterm infants: Risk/benefit ratio;Corticothérapie post-natale chez le prématuré: Bénéfices et risques

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 34, Issue 1 SUPPL., 2005, Pages

  Baud, O ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

Bronchopulmonary dysplasia; Hemodynamic failure; Post natal corticosteroid therapy; Preterm birth

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID; STEROID;

ASSISTED VENTILATION; BRAIN DEVELOPMENT; CEREBRAL PALSY; CONFERENCE PAPER; DIGESTIVE SYSTEM PERFORATION; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LUNG DYSPLASIA; NEUROLOGIC DISEASE; NEWBORN; NEWBORN MORTALITY; PREMATURITY; RISK BENEFIT ANALYSIS; STEROID THERAPY; ANIMAL; BRAIN DISEASE; REVIEW; RISK ASSESSMENT;

ANIMALS; BRAIN DISEASES; DEXAMETHASONE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; RISK ASSESSMENT; STEROIDS;

EID: 13444250947     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (68)

1. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 1972; 50: 515-25.
2. Crowley P, Chalmers I, Keirse MJNC. The effects of corticosteroid administration before preterm delivery: an overview of the evidence from controlled trials. Br J Obstet Gynaecol 1990; 97: 133.
3. Consensus Development Panel. Effect of corticosteroids for fetal maturation on perinatal outcomes. National Institutes of Health Conference Statement. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health 1994 Feb 28-Mar 2; 12: 1-24.
4. Rennie JM, Wheater M, Cole TJ. Antenatal steroid-administration is associated with an improved chance of intact survival in preterm infants. Eur J Pediatr 1996; 155: 576-9.
5. Crowley P. Prophylactic corticosteroids for preterm birth. Cochrane Database Syst Rev 2003: 1.
6. Haddad H, Hsia D, Gellis S. Studies on respiratory rate in the newborn. Its use in the evaluation of RDS in IDM. Pediatrics 1956; 17: 204-12.
7. Baden M, Bauer CR, Colle E, Klein G, Taeusch HW Jr, Stem L. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. J Pediatr 1972; 50: 526-34.
8. Mammel MC, Green TP, Johnson DE, Thompson TR. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet 1983; 1: 1356-8.
9. Avery GB, Fletcher AB, Kaplan M, Brudno DS. Controlled trial of dexamethasone in respirator dependent infants with bronchopulmonary dysplasia. Pediatrics 1985; 75: 106-11.
10. Bhuta T, Ohlsson A. Systematic review and meta-analysis of early post-natal dexamethasone for prevention of chronic lung disease. Arch Dis Child Fetal Neonatal Ed 1998; 79: F26-33.
11. Halliday HL. Clinical trials of post-natal corticosteroids: inhaled and systemic. Biol Neonate 1999; 76 (suppl 1): 29-40.
12. Larroque B, Samain H. Groupe Epipage. Epipage study: mortality of very premature infants and state of progress at follow up. J Gynecol Obstet Biol Reprod 2001; 30: S33-41.
13. Lee SK, McMillan DD, Ohlsson A, Pendray M, Synnes A, Whyte R et al. Variations in practice and outcomes in the Canadian NICU Network: 1996-1997. Pediatrics 2000; 106: 1070-9.
14. Lemons JA, Bauer CR, Oh W, Korones SB, Papile LA, Stoll BJ et al. Very low birth weight outcomes of the National Institutes of Child Health and Human Development Neonatal Research Network, january 1995 through december 1996. Pediatrics 2001; 107: E1.
15. Jobe AH, Ikegami M. Mechanisms initiating lung injury in the preterm. Early Hum Dev 1998; 53: 81-94.
16. Kopelman AE, Moise AA, Holbert D, Hegemier SE. A single very early dexamenthasone dose improves respiratory and cardiovascular adaptation in preterm infants. J Pediatr 1999; 735: 345-50.
17. Seri I, Tan R, Evans J. Cardiovascular effects of hydrocortisone in preterm infants with pressor-resistant hypotension. Pediatrics 2001; 107: 1070-4.
18. Watterberg KL, Gerdes JS, Cook KL. Impaired glucocorticoid synthesis in premature infants developing chronic lung disease. Pediatr Res 2001; 50: 190-5.
19. Halliday HL, Ehrenkranz RA. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; 1: CD001146.
20. Halliday HL, Ehrenkranz RA. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; 1: CD001144.
21. Halliday HL, Ehrenkranz RA. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; 1: CD001145.
22. Stark AR, Carlo WA, Tyson JE, Papile LA, Wright LL, Shankaran S et al. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 2001; 344: 95-101.
23. Yeh TF, Lin YJ, Huang CC, Chen YJ, Lin CH, Lin HC et al. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics 1998; 101: E7.
24. Shinwell ES, Karplus M, Reich D, Weintraub Z, Blazer S, Bader D et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed 2000; 83: F177-81.
25. O'Shea TM, Kothadia JM, Klinepeter KL, Goldstein DJ, Jackson BG, Weaver RG et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics 1999; 104: 15-21.
26. Baud O. Is perinatal dexamethasone treatment safe in preterm infants? Dev Med Child Neurol 2001; 86 (suppl): 23-5.
27. Barrington KJ. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr 2001; 1: 1.
28. Halliday HL. Early postnatal dexamethasone and cerebral palsy. Pediatrics 2002; 109: 1168-9.
29. Yeh TF, Lin YJ, Lin HC, Huang CC, Hsieh WS, Lin CH, Tsai CH. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 2004; 350: 1304-13.
30. Bos AF, Martijn A, van Asperen RM, Hadders-Algra M, Okken A, Prechtl HF. Qualitative assessment of general movements in high-risk preterm infants with chronic lung disease requiring dexamethasone therapy. J Pediatr 1998; 132: 300-6.
31. Kuban KC, Leviton A. Cerebral palsy. N Engl J Med 1994; 330: 188-95.
32. Inder TE, Huppi PS, Warfield S, Kikinis R, Zientara GP, Barnes PD et al. Periventricular white matter injury in the premature infant is followed by reduced cerebral cortical gray matter volume at term. Ann Neurol 1999; 46: 755-60.
33. Ajayi-Obe M, Saeed N, Cowan FM, Rutherford MA, Edwards AD. Reduced development of cerebral cortex in extremely preterm infants. Lancet 2000; 356: 1162-3.
34. Murphy BP, Inder TE, Huppi PS, Warfield S, Zientara GP, Kikinis R et al. Impaired cerebral cortical gray matter growth after treatment with dexamethasone for neonatal chronic lung disease. Pediatrics 2001; 107: 217-21.
35. Modi N, Lewis H, Al-Naqeeb N, Ajayi-Obe M, Dore CJ, Rutherford M. The effects of repeated antenatal glucocorticoid therapy on the developing brain. Pediatr Res 2001; 50: 581-5.
36. Dobbing J. The later development of the brain and its vulnerability. In: Scientific Foundation of paediatrics, edited by Davis JA and Dobbing J. London: Heineman, p565-77.
37. Saliba E, Marret S. Cerebral white matter damage in the preterm infant: pathophysiology and risk factors. Semin Neonatol 2001; 6: 121-33.
38. Dammann O, Leviton A. Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. Pediatr Res 1997; 42: 1-8.
39. Yoon BH, Romero R, Yang SH, Jun JK, Kim IO, Choi JH et al. Interleukin-6 concentrations in umbilical cord plasma are elevated in neonates with white matter lesions associated with periventricular leukomalacia. Am J Obstet Gynecol 1996; 174: 1433-40.
40. Nelson KB, Dambrosia JM, Grether JK, Phillips TM. Neonatal cytokines and coagulation factors in children with cerebral palsy. Ann Neurol 1998; 44: 665-75.
41. Volpe JJ. Neurobiology of periventricular leukomalacia in the premature infant. Pediatr Res 2001; 50: 553-62.
42. Back SA, Han BH, Luo NL, Chricton CA, Xanthoudakis S, Tam J et al. Selective vulnerability of late oligodendrocyte progenitors to hypoxia-ischemia. J Neurosci 2002; 22: 455-63.
43. Kauffman F, Seidler FJ, Slotkin TA. Prenatal dexamethasone exposure causes loss of neonatal hypoxia tolerance: cellular mechanisms. Pediatr Res 1994; 35: 515-22.
44. Tombaugh GC, Yang SH, Swanson RA, Sapolsky RM. Glucocorticoids exacerbate hypoxic and hypoglycaemic hippocampal injury in vitro. J Neurochem 1992; 59: 137-46.
45. Prodanov D, Mantchev G, Iliev A, Traykov V, Yakimova K, Kaneva R et al. Effects of dexamethasone in rat neonatal model of axotomy-induced motoneuronal cell death. Arch Physiol Biochem 1998; 106: 355-61.
46. Tsubota S, Adachi N, Chen J, Yorozuya T, Nagaro T, Arai T. Dexamethasone changes brain monoamine metabolism and aggravates ischemic neuronal damage in rats. Anesthesiology 1999; 90: 515-23.
47. Tuor UI, Chuman PD, Del Bigio MR. Prevention of hypoxic-ischaemic damage with dexamethasone is dependent on age and not influenced by fasting. Exp Neurol 1995; 132: 116-22.
48. Flavin MP. Influence of dexamethasone on neurotoxicity caused by oxygen and glucose deprivation in vitro. Exp Neurol 1996; 139: 34-8.
49. Arquie C, Leroux P, Bodenant C, Laquerriere A, Marpeau L, Marret S. Glucocorticoid treatment in an ischaemic-like excitotoxic model of periventricular leucomalacia in mice. Br J Obstet Gynaecol 2002; 109: 989-96.
50. Riva MA, Fumagalli F, Racagni G. Opposite regulation of basic fibroblast growth factor and nerve growth factor gene expression in rat cortical astrocytes following dexamethasone administration. J Neurochem 1995; 64: 2526-33.
51. Sysyn GD, Petersson KH, Patlak CS, Sadowska GB, Stonestreet BS. Effects of postnatal dexamethasone on blood-brain barrier permeability and brain water content in newborn lambs. Am J Physiol Regl Integr Comp Physiol 2001; 280: R547-53.
52. Weichsel ME. The therapeutic use of glucocorticoid hormones in the perinatal period. Potential neurological hazards. Ann Neurol 1977; 46: 364-6.
53. Benesova O, Pavlik A. Perinatal treatment with glucocorticoids and the risk of maldevelopment of the brain. Neuropharmacology 1989; 28: 89-97.
54. McGowan JE, Sysyn G, Petersson KH, Sadowska GB, Mishra OP, Delivoria-Papadopoulos M et al. Effect of dexamethasone treatment on maturational changes in the NMDA receptor in sheep brain. J Neurosci 2000; 20: 7424-9.
55. Marret S, Gressens P, Evrard P. Arrest of neuronal migration by excitatory amino acids in hamster developing brain. Proc Natl Acad Sci USA 1996; 93: 15463-8.
56. Tahraoui SL, Marret S, Bodenant C, Leroux P, Dommergues MA, Evrard P et al. Central role of microglia in neonatal excitotoxic lesions of the murine periventricular white matter. Brain Pathol 2001; 11: 56-71.
57. Reist M, Marshall KA, Jenner P, Halliwell B. Toxic effects of sulfite in combination with peroxynitrite on neuronal cells. J Neurochem 1998; 71: 2431-8.
58. Baud O, Foix-L'Helias L, Kaminski M, Audibert F, Jarreau PH, Papiernik E et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med 1999; 341: 1190-6.
59. Baud O, Laudenbach V, Evrard P, Gressens P. Neurotoxic effects of fluorinated glucocorticoid preparations on the developing mouse brain: role of preservatives. Pediatr Res 2001; 50: 706-11.
60. Schwab M, Antonow-Schlorke I, Kuhn B, Muller T, Schubert H, Walter B et al. Effect of antenatal betamethasone treatment on microtubule-associated proteins MAP1B and MAP2 in fetal sheep. J Physiol 2001; 530: 497-506.
61. Flagel SB, Vazquez DM, Watson SJ Jr, Neal CR Jr. Effects of tapering neonatal dexamethasone on rat growth, neurodevelopment, and stress response. Am J Physiol Regul Integr Comp Physiol 2002; 282: R55-63.
62. Baud O, Verney C, Evrard P, Gressens P. Injectable dexamethasone administration enhances cortical GABAergic neurons maturation in a murine model of postnatal steroid therapy. Pediatr Res 2005; 57: 149-56.
63. Stone DJ, Walsh JP, Sebro R, Stevens R, Pantazopolous H, Benes FM. Effects of pre- and postnatal corticosterone exposure on the rat hippocampal GABA system. Hippocampus 2001; 11: 492-507.
64. Watterberg KL, Gerdes JS, Gifford KL, Lin HM. Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics 1999; 104: 1258-63.
65. Watterberg KL, PROPHET study group. Prophylaxis of early adrenal insufficiency to prevent BPD: multicenter trial. APS meeting 2004. Pediatr Res 2004; 55: 465A (abstract 2642).
66. Lodygensky GA, Rademaker K, Zimine S. Structural and functional brain development after hydrocortisone treatment for neonatal chronic lung disease. Pediatrics (in press).
67. Andre P, Thebaud B, Odievre MH, Razafimahefa H, Zupan V, Dehan M et al. Methylprednisolone, an alternative to dexamethasone in very premature infants at risk of chronic lung disease. Intensive Care Med 2000; 26: 1496-500.
68. Shah SS, Ohlsson A, Halliday H, Shah VS. Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev 2003; 1: CD002058.